• Premier Biomedical Realigns Business to Eliminate Convertible Debt, Cancel Reverse Split & Fund Covid-19 R&D

    1 month ago - By Premier Biomedical

    Jackson Center, PA, April 6, 2020 - Premier Biomedical, Inc. announced a multi-faceted agreement to eliminate the Convertible Notes as an obligation of Premier, cancel the previously announced plans for a reverse split, and secure near-term funding for ongoing R&D into a potential cure for Covid-19 as well as Premier's Anti-Addiction Patch .
    William A. Hartman, President and CEO of Premier Biomedical, Inc., stated, “These are bold giant steps that we are taking for the benefit of our country, our company, and our stockholders. We believe that our patented twin technologies will produce...
    Read more ...

     

  • Wellcome targets $8B raise in weeks to fix COVID-19 funding gap

    Wellcome targets $8B raise in weeks to fix COVID-19 funding gap

    1 month ago - By Fierce Biotech

    Wellcome is calling on businesses to invest in an $8 billion fund focused on reducing cases of COVID-19 to zero as soon as possible. Almost half the money is earmarked for the development of drugs and vaccines that Wellcome sees as the “world's best exit strategy” from the pandemic.
    Read more ...